SHIODA MUKUTO

Profiles

Profiles

• 氏名

  SHIODA MUKUTO

Affiliation

• Department of Neurology

Research achievements

Published Papers

Original paper
• Real-world achievement of higher standards for migraine prevention with CGRP monoclonal antibodies., Suzuki Keisuke;Suzuki Shiho;Kobayashi Saro;Shioda Mukuto;Fujita Hiroaki;Haruyama Yasuo;Hida Ryotaro;Hirata Koichi, Cephalalgia : an international journal of headache, 46(6), 3331024261453284, 01 Jun. 2026

  DOIPermalink
• Interictal thermal pain hypersensitivity and central sensitization in migraine patients: a case-control study using quantitative sensory testing., Suzuki Keisuke;Suzuki Shiho;Haruyama Yasuo;Shioda Mukuto;Kobayashi Saro;Hida Ryotaro;Hirata Koichi, Head & face medicine, 20 Mar. 2026

  DOIPermalink
• A Real-World Study of CGRP Monoclonal Antibodies for Migraine: Long-Term Effectiveness and Treatment Adherence., Suzuki Keisuke;Suzuki Shiho;Kobayashi Saro;Shioda Mukuto;Fujita Hiroaki;Haruyama Yasuo;Hirata Koichi, European journal of neurology, 33(3), e70562, Mar. 2026

  DOIPermalink
• A real-world study of the efficacy and tolerability of fremanezumab in migraine patients with a median follow-up of 14 months., Suzuki Shiho;Suzuki Keisuke;Haruyama Yasuo;Fujita Hiroaki;Shiina Tomohiko;Kobayashi Saro;Shioda Mukuto;Hida Ryotaro;Hirata Koichi, Neurological research and practice, 7(1), 37, 03 Jun. 2025

  DOIPermalink
• The effect of calcitonin gene-related peptide monoclonal antibodies on restless legs syndrome in patients with migraine., Suzuki Keisuke;Suzuki Shiho;Fujita Hiroaki;Kobayashi Saro;Shioda Mukuto;Hida Ryotaro;Hirata Koichi, The journal of headache and pain, 26(1), 36, 19 Feb. 2025

  DOIPermalink
• Real-world effectiveness of erenumab in Japanese patients with migraine., Suzuki Keisuke;Suzuki Shiho;Shiina Tomohiko;Haruyama Yasuo;Kobayashi Saro;Shioda Mukuto;Hirata Koichi, Heliyon, 10(4), e26568, 17 Feb. 2024

  DOIPermalink
• 1(3), 181-np1, Sep. 2022

  Permalink

Review paper
• 21(3), 258-261, Feb. 2022

  Permalink

Case report
• Can calcitonin gene-related peptide monoclonal antibodies ameliorate writer's cramp and migraine?, Suzuki Keisuke;Suzuki Shiho;Fujita Hiroaki;Sakuramoto Hirotaka;Shioda Mukuto;Hirata Koichi, Neuropsychopharmacology reports, 11 Apr. 2024

  DOIPermalink
• Gait instability, ophthalmoplegia, and chorea with orofacial dyskinesia in a man with anti-Ri antibodies: a case report., Shioda Mukuto;Fujita Hiroaki;Onuma Hiroki;Sakuramoto Hirotaka;Hamaguchi Mai;Suzuki Keisuke, Frontiers in neurology, 15, 1359781, 20 Mar. 2024

  DOIPermalink
• Anti-LGI1 encephalitis recurring 3 years after the first episode: a case report., Fujita Hiroaki;Shioda Mukuto;Suzuki Keisuke, BMC neurology, 22(1), 148, 21 Apr. 2022

  DOIPermalink
• Transient glyphosate encephalopathy due to a suicide attempt., Yokoyama Saaya;Sugisaki Tomomi;Ryota Yoshida;Yoshiteru Sato;Okayasu Hiroaki;Shioda Mukuto;Suzuki Keisuke;Yasui-Furukori Norio;Shimoda Kazutaka, Neuropsychopharmacology reports, 41(3), 444-447, 06 Aug. 2021

  DOIPermalink

Other
• Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule., Suzuki Shiho;Suzuki Keisuke;Shiina Tomohiko;Kobayashi Saro;Shioda Mukuto;Hirata Koichi, Journal of the neurological sciences, 455, 122786, 13 Nov. 2023

  DOIPermalink